Related Experiment Video

Updated: Jun 7, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

Apolipoprotein A-I mimetic peptides

G K Hovingh1, Andrea E Bochem, John J P Kastelein

  • 1Department Vascular Medicine, Academic Medical Center, Meibergdreef 9 F4-159.2, 1100DD Amsterdam, The Netherlands. g.k.hovingh@amc.uva.nl

Current Opinion in Lipidology
|November 3, 2010
PubMed

Insights

Apolipoprotein A-I (apoA-I) mimetic peptides show promise for treating atherosclerosis by enhancing HDL functionality, not just levels. These mimetics offer anti-inflammatory and antiatherogenic effects, with potential applications in various diseases.

Area of Science:

  • Biochemistry
  • Cardiovascular Research
  • Pharmacology

Background:

  • High-density lipoprotein cholesterol (HDL-C) levels correlate with cardiovascular disease (CVD) risk, but raising HDL-C alone has not consistently reduced CVD risk.
  • Increasing HDL functionality, rather than just cholesterol levels, may be a more effective strategy for reversing atherosclerosis.
  • Apolipoprotein A-I (apoA-I) mimetic peptides are being investigated as a novel therapeutic approach.

Purpose of the Study:

  • To review existing literature on the potential therapeutic applications of apoA-I mimetic peptides.
  • To evaluate the evidence for apoA-I mimetics in influencing cardio-metabolic pathways.
  • To summarize the current understanding of apoA-I mimetics as potential therapeutic agents.

Main Methods:

  • Literature review of published data on apoA-I mimetic peptides.
  • Analysis of studies investigating the effects of mimetics on cardio-metabolic pathways.
  • Comparison of different mimetic formulations and their effects.

Main Results:

  • ApoA-I mimetics demonstrate anti-inflammatory, antioxidant, and antiatherogenic properties.
  • Evidence suggests that apoA-I mimetics can influence multiple cardio-metabolic pathways.
  • Studies indicate potential therapeutic roles in conditions such as septicaemia, transplant rejection, diabetes, and autoimmune diseases.

Conclusions:

  • ApoA-I mimetic peptides represent a promising therapeutic strategy, potentially supplementing current treatments.
  • Further in-vivo human studies are needed to confirm the efficacy of various apoA-I mimetics.
  • The focus is shifting from raising HDL-C to improving HDL functionality for cardiovascular health.
Abstract

More Related Videos

Production and Testing of Antimicrobial Peptides and Their Mimics10:35

Production and Testing of Antimicrobial Peptides and Their Mimics

Published on: April 10, 2026

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain10:08

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain

Published on: August 28, 2012

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...